<qa>  What is the initial dose of PN containing Omegaven?This compassionate use study will include patients with advanced cancer requiring PN for long-term nutrition support who have developed PN-induced hepatic injury or who have existing hepatic dysfunction. Therapy with Omegaven will be provided at an initial dose of 0.1 gkg body weight 1mlkg and increased to 0.2 gkg body weight 2mlkg on day 2 or 3 of treatment. For patients 120 ideal body weight, adjusted body weight will be used. The infusion rate will not exceed 0.5mL Omegavenkg body weighthr corresponding to 0.05g fish oilkghr. Omegaven will be co-administered via a y-site infusion, with containers being changed every 12 hours. The patient may receive other lipids to meet Essential Fatty Acid EFA andor additional calorie needs. Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center MRMC in the infusion center to observe for adverse reactions. If an adverse reaction is observed, IV steroids benadryl will be administered Omegaven will be discontinued. Patients will continue to receive infusions at CTCA for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home with Coram. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month see Table 2. 